The table below indicates the characteristics of patients included in the FOXFIRE Combined Analysis. There were no significant differences in baseline patient characteristics. A majority of patients had poor prognostic factors at baseline: almost 90% of patients had synchronous disease, more than half of the patients had primary tumour in situ and more than a third of the patients had extra-hepatic metastases.
*Biologic agents: Bevacizumab in SIRFLOX and FOXFIRE Global. Bevacizumab or cetuximab in FOXFIRE. Biologicals allowed at investigator’s discretion, per institutional practice.
Wasan HS et al. Lancet Oncol 2017; 18: 1159-71.